BSMHWebadmin, Author at Clinical Trials Portal

Alliance 212102

Alliance Protocol A212102, “Blinded Reference Set for Multicancer Early Detection Blood Tests”

https://www.clinicaltrials.gov/ct2/show/NCT05334069?term=NCT05334069&draw=2&rank=1

EA1151-TMIST

EA1151 Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

S2001

“Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations”

A021703

RANDOMIZED DOUBLE-BLIND PHASE III TRIAL OF VITAMIN D3 SUPPLEMENTATION IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (SOLARIS)

URCC21038

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT):A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

S1900E

A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)”

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)(NCT04181060)

NRG-GI008

COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)

SWOG 2001

A Phase II Trial of Sacituzumab Govitecan (TRODELVY™) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases

S2007